Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;105(5):e210-e212.
doi: 10.3324/haematol.2019.222471. Epub 2019 Sep 12.

Ruxolitinib for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis

Affiliations
Free PMC article

Ruxolitinib for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis

Jingshi Wang et al. Haematologica. .
Free PMC article

Figures

Figure 1
Figure 1
Survival of patients with refractory/relapsed hemophagocytic lymphohistiocytosis treated with ruxolitinib. (A) Overall survival (OS). (B) Progression-free survival (PFS). The median survival time was 22 weeks (range: 4-52 weeks). The median PFS time was eight weeks (range: 2-40 weeks). Cum Survival: cumulative survival.

Similar articles

See all similar articles

Cited by 1 article

LinkOut - more resources

Feedback